, received a new
innovation patent right on April 14, 2005 by China's State Intellectual
Property Bureau, for the manufacturing processes relating to the extraction
and purification of echinocystic acid from the pod of gleditsia sinensis lam.
"At Global Pharmatech, we are always striving for innovation in our drug
products whether that is in drug manufacturing or research and development. Global Pharmatech
offers a full range of "start to finish" biotech services, from R +D and
testing, to manufacturing drugs in liquid and solid dose forms, to sales and
marketing.

maintained cytokines

, Dynavax Technologies
(Nasdaq: DVAX) announced today that Dino Dina, MD, President and CEO, will
present an overview of the company at the Thomson Financial/BioCentury Future
Leaders in the Biotech Industry conference at the Millennium Broadway hotel in
New York City.corporate-ir.

lymphatic immunology

Contact: Ingrid Shieh
Investor Relations
The Anne McBride Co.

allergies biology

Echinocystic acid is the active ingredient in the pod of gleditsia
sinensis lam.

cytokines biology

Global Pharmatech Receives New Innovation Patent Right for its Extraction and Purification Methodologies of Echinocystic Acid

responses stages

methods emigrate

Global Pharmatech's core
business to date has been licensing its R+D patents and technologies for
botanical /biological drug products.

biology homing

(OTC PK: GBLP), a company which combines R+D of botanical drug products ,
manufacturing, and sales and marketing for the Over-the-Counter (OTC) and
prescription drug markets , announced that Jilin Natural Pharmatech Group Co.

homing vaccination

Based on the results of pharmacology studies , echinocystic acid has the
potential to become a potent drug product for the prevention and treatment of
heart and cardiovascular diseases.

stages methods

To date,
increasing risk factors have resulted in an estimated 10+ million
cardiovascular disease patients in China.

recirculate allergies

212-983-1702 x218
Email: ishieh@annemcbride. Dina's presentation will be webcast live at 11:40 am ET on Thursday ,
April 7, 2005. Our
clinical development programs are based on immunostimulatory sequences, or
ISS, which are short DNA sequences that enhance the ability of the immune
system to fight disease and control chronic inflammation.

leukocyte biology

Our expertise comes from our team's wealth of experience in Traditional
Chinese Medicine (TCM) and our focus on producing more effective forms of TCM
drugs to treat prevailing diseases in China," said Dr.zhtml?ticker=DVAX+item_id=1015249,
where it will also be archived for 30 days following the presentation.

immune maintained

Sun Xiaobo, President
and CEO of Global Pharmatech.

ABOUT GLOBAL PHARMATECH
Global Pharmatech, through its subsidiaries, develops, manufactures and
markets proprietary drugs that are based on Traditional Chinese Medicine while
utilizing modern facilities and advanced R+D technologies. BERKELEY, Calif. The webcast presentation may be accessed by visiting
http://www.

cascade vaccination

Ltd.

inflammation responses

Global Pharmatech utilizes unique extraction methods and innovative
techniques that have been developed by its R+D team. Our actual results may differ materially
and adversely from those expressed in any forward-looking statements as a
result of various factors and uncertainties, including the recent economic
slowdown affecting technology companies, our ability to successfully develop
products, rapid technological change in our markets, changes in demand for our
future products, legislative, regulatory and competitive developments and
general economic conditions.com

lymphatic cytokines

Over the past twenty years in China, there has been a significant rise in
diagnosed cases of cardiovascular disease.
Dr.

stages responses

These statements are based upon our current expectations and
speak only as of the date hereof.

About Dynavax
Dynavax Technologies Corporation discovers, develops, and intends to
commercialize innovative products to treat and prevent allergies, infectious
diseases, and chronic inflammatory diseases using versatile , proprietary
approaches that alter immune system responses in highly specific ways. ISS are being
developed in three initial indications: ragweed allergy immunotherapeutic,
currently in a Phase 2/3 clinical trial; a Hepatitis B vaccine, currently in a
Phase 2/3 clinical trial; and an asthma immunotherapeutic that has completed a
Phase 2 exploratory trial.

immune allergies

JILIN, China, July 11 /Xinhua -PRNewswire/ -- Global Pharmatech, Inc.

inflammation tissue

Jilin Natural Pharmatech Group has filed an
Investigational New Drug (IND) application for echinocystic acid to the State
Food and Drug Administration (SFDA ), the Chinese regulatory authority, in
order to initiate clinical trials. Our SEC filings discuss some of the important
risk factors that may affect our business, results of operations and financial
condition.

adhesion emigrate

net/ireye/confLobby.

maintained adhesion

We undertake no obligation to revise or update publicly any
forward-looking statements for any reason.

Dynavax to Webcast Presentation at Future Leaders in the Biotech Industry Conference April 7 2005

inflammation immune

Safe Harbor Statement under the Private Securities Litigation Reform Act
of 1995
This news release contains forward-looking statements within the meaning
of the "safe harbor" provisions of the Private Securities Litigation Reform
Act of 1995.

lymphocyte cytokines

This patent also protects medical use of echinocystic acid for
the treatment and prevention of cardiovascular disease.

recirculate vaccination

Global Pharmatech's operations are
currently based in the People's Republic of China with sales distribution in
China, Malaysia, Singapore and Indonesia.

monitoring leukocyte

, a company wholly owned by Global Pharmatech, Inc. The State Health Authority's
statistics show that the number one cause of deaths in China is from
cardiovascular disease as the result of changing lifestyles.